Adial Pharmaceuticals, Inc. Restructuring Costs
Adial Pharmaceuticals, Inc. (ADIL) reported Restructuring Costs of $143.10 thousand for the 9-month period ending 2023-09-30, per its 10-Q filed 2023-11-14.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:RestructuringCosts · last filed 2023-11-14
- Adial Pharmaceuticals, Inc. restructuring costs for the quarter ending 2023-09-30 was $66.00K.
| Period end | Restructuring Costs 3 month | Restructuring Costs 6 month | Restructuring Costs 9 month |
|---|---|---|---|
| 2023-09-30 | $66.00K derived: 10-Q 9 month − 10-Q/A 6 month · filed 2023-11-14 | $143.10K 10-Q · filed 2023-11-14 | |
| 2023-06-30 | $77.10K 10-Q/A · filed 2023-10-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |